Ad
related to: benlysta injection site- About Chronic ITP
Learn More About What It Is
& How It Is Treated.
- Connect With Coordinators
Click To Download Our Forms
Or Get Assistance.
- Join For Exclusive Tips
Sign Up For Our Community Tips
Delivered To Your Doorstep & Inbox
- View Prescribing Info
Click To Find Full Prescribing
Info For This Medication.
- About Chronic ITP
Search results
Results from the WOW.Com Content Network
Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), [6] also known as B-lymphocyte stimulator (BLyS). [7] It is approved in the United States [ 8 ] and Canada, [ 9 ] and the European Union [ 5 ] to treat systemic lupus erythematosus and lupus nephritis.
Belantamab mafodotin was evaluated in DREAMM-2 (NCT 03525678), an open-label, multicenter trial. [5] Participants received either belantamab mafodotin, 2.5 mg/kg or 3.4 mg/kg intravenously, once every three weeks until disease progression or unacceptable toxicity.
OnPoint NYC is a New York City nonprofit that operates two privately run safe injection sites (also known as Overdose Prevention Centers) in East Harlem and Washington Heights. [2] Placed at the sites of existing syringe service programs, [3] these were America's first safe injection facilities when they opened in November 2021. [2]
Clinical trial number NCT05232825 for "A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis (Ocarina II)" at ClinicalTrials.gov
Bimekizumab, sold under the brand name Bimzelx (/ b ɪ m ˈ z ɛ l ɪ k s / bim-ZEL-iks), is a humanized anti-IL17A, anti-IL-17F, and anti-IL17AF monoclonal antibody [6] [7] that is used to treat plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, and hidradenitis suppurativa.
Benralizumab, sold under the brand name Fasenra, is a monoclonal antibody directed against the alpha chain of the interleukin-5 receptor ().It was developed by MedImmune for the treatment of asthma.
Injection site reactions such as redness and pain are common, occurring in approximately 15.5% of cases. [11] The FDA prescribing information for canakinumab (Ilaris) includes a warning for potential increased risk of serious infections due to IL-1 blockade. [4]
Golimumab, sold under the brand name Simponi, is a human monoclonal antibody which is used as an immunosuppressive medication. [3] [5] Golimumab targets tumor necrosis factor alpha (TNF-alpha), a pro-inflammatory molecule [6] and hence is a TNF inhibitor.
Ad
related to: benlysta injection site